Eli Lilly and Company

2321 articles with Eli Lilly and Company

• Innovent Provides Updates on Extended Follow-up on Sintilimab for Relapsed/Refractory Classical Hodgkin's Lymphoma

  6/4/2019

  Innovent Biologics, Inc. announced that the results of extended follow-up on sintilimab, the anti-PD-1 antibody that co-developed with Eli Lilly and Company, for relapsed/refractory classical Hodgkin's lymphoma were presented by poster at the 55th annual meeting of the American Society of Clinical Oncology

• Updated Results on Neoadjuvant PD-1 Blockade with Sintilimab in Resectable Squamous Non-Small Cell Lung Cancer (sqNSCLC) at ASCO, Led by Professor Jie He, Dean of the Cancer Hospital of the Chinese Academy of Medical Sciences

  6/3/2019

  The preliminary results of efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer, led by Professor Jie He, Dean of the Cancer Hospital of the Chinese Academy of Medical Sciences, were presented by poster at the 55th annual meeting of the American Society of Clinical Oncology.

• Atomwise Announces Multi-year, Multi-target Agreement with Lilly for AI-Driven Drug Discovery Program

  6/3/2019

  The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of accelerating the time it takes to identify and develop potential new medicines.

• Innovent Provides Update on Phase Ib Study of Sintilimab in Combination with Chemotherapy for First-line Advanced or Metastatic Non-small Cell Lung Cancer

  5/31/2019

  Innovent Biologics, Inc. announced that the preliminary results of sintilimab, the anti-PD-1 antibody that co-developed with Eli Lilly and Company, in combination with chemotherapy for 1L advanced or metastatic non-small cell lung cancer were presented at the 55th Annual Meeting of the American Society of Clinical Oncology

• Hurricane Season is Almost Here. Are You Ready?

  5/31/2019

  Lilly, Healthcare Ready and Direct Relief Helping People Prepare for Disasters, Ensure Medicines are Available

• Lilly to Participate in Goldman Sachs Global Healthcare Conference - May 30, 2019

  5/30/2019

  Eli Lilly and Company will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019.

• Lilly Announces Webcast to Discuss ADA Presentations and Diabetes Portfolio

  5/29/2019

  Eli Lilly and Company will conduct a webcast on Monday, June 10, 2019 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's 79th Scientific Sessions in San Francisco, California.

• Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics

  5/28/2019

  Eli Lilly and Company announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain.

• 

  Eli Lilly In-Licenses Non-Opioid Drug from Centrexion in $997 Million-Plus Deal

  5/28/2019

  Eli Lilly announced it has inked a license agreement with Centrexion Therapeutics to acquire the exclusive global rights to CNTX-0290.
• 

  Clinical Catch-up from Last Week: May 20-24

  5/28/2019

  Here’s a roundup of some of the top clinical trial news from the previous week.
• 

  Eli Lilly’s Generic Insulin Hits Market at Half the Price of Branded Counterpart

  5/23/2019

  Lispro Injection is a generic of Eli Lilly's Humalog that is now available to diabetes patients at a 50% lower list price.

• Lilly's Lower-Priced Insulin Now Available

  5/22/2019

  List price of Lilly's Insulin Lispro Injection 50 percent less than branded Humalog

• Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions

  5/21/2019

  In an oral presentation from the Digestive Disease Week medical conference in San Diego, California today, Eli Lilly and Company (NYSE: LLY) announced new safety and efficacy data for mirikizumab in patients with moderately- to severely active Crohn's disease.

• Lilly to Participate in UBS Global Healthcare Conference

  5/16/2019

  Christi Shaw, president of Lilly Bio-Medicines, will participate in a fireside chat at 9:30 a.m., Eastern Time.

• Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2019 Annual Meeting

  5/16/2019

  Flatiron Health announced 16 abstracts accepted for presentation at the 2019 American Society for Clinical Oncology Annual Meeting, which will be held May 31 - June 4 in Chicago.

• Innovent Will Provide Key Results Update of Several Clinical Studies at 2019 ASCO Annual Meeting

  5/16/2019

  Oral presentation on the results of sintilimab for relapsed/refractory extranodal NK/T cell lymphoma

• Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer

  5/15/2019

  Eli Lilly and Company announced that data from a number of studies across the company's oncology product portfolio will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019.

• Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma

  5/13/2019

  Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein (AFP) of ≥400 ng/mL and have been treated with sorafenib.

• ICON Awarded Clinical Research Team of the Year and Best in Health Economics and Outcomes Research

  5/13/2019

  ICON Wins Multiple Awards at the 2019 Clinical and Research Excellence Awards

• 

  Eli Lilly’s Cyramza Approved for HCC Patients, Boxed Warning Label Removed by FDA

  5/13/2019

  The drug was approved as a second-line treatment for HCC patients who have an alpha-fetoprotein biomarker.